Quality key factors
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-9.25%
EBIT to Interest (avg)
-27.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.79
Sales to Capital Employed (avg)
2.82
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
0.55
EV to EBITDA
0.63
EV to Capital Employed
-3.66
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-141.94%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Technical Movement
5What is working for the Company
NET PROFIT(HY)
Higher at SEK -12.68 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -79.34 %
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Coegin Pharma AB
Net Profit
Higher at SEK -12.68 MM
than preceding 12 month period ended Mar 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
Debt-Equity Ratio
Lowest at -79.34 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales






